IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-03783819.html
   My bibliography  Save this paper

Cost-Effectiveness of an Organized Lung Cancer Screening Program for Asbestos-Exposed Subjects

Author

Listed:
  • Sébastien Gendarme

    (CHIC - Centre Hospitalier Intercommunal de Créteil, IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, CEpiA - Clinical Epidemiology and Ageing : Geriatrie Soins Primaires et Santé Publique - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12)

  • Jean-Claude Pairon

    (IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, CHIC - Centre Hospitalier Intercommunal de Créteil, IIMTPIF - Institut Interuniversitaire de Médecine du Travail de Paris Ile-de-France)

  • Pascal Andujar

    (IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, CHIC - Centre Hospitalier Intercommunal de Créteil, IIMTPIF - Institut Interuniversitaire de Médecine du Travail de Paris Ile-de-France)

  • François Laurent

    (CRCTB - Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] - Université Bordeaux Segalen - Bordeaux 2 - CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux - INSERM - Institut National de la Santé et de la Recherche Médicale)

  • Patrick Brochard

    (CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux, EPICENE - Cancer environnement - BPH - Bordeaux population health - UB - Université de Bordeaux - Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED) - INSERM - Institut National de la Santé et de la Recherche Médicale)

  • Fleur Delva

    (EPICENE - Cancer environnement - BPH - Bordeaux population health - UB - Université de Bordeaux - Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED) - INSERM - Institut National de la Santé et de la Recherche Médicale)

  • Bénédicte Clin

    (CHU Caen - NU - Normandie Université - TCBN - Tumorothèque de Caen Basse-Normandie, UNICAEN - Université de Caen Normandie - NU - Normandie Université)

  • Antoine Gislard

    (ABTE - Aliments Bioprocédés Toxicologie Environnements - UNICAEN - Université de Caen Normandie - NU - Normandie Université - UNIROUEN - Université de Rouen Normandie - NU - Normandie Université, CHU Rouen - NU - Normandie Université)

  • Christophe Paris

    (CHIC - Centre Hospitalier Intercommunal de Créteil)

  • Isabelle Thaon

    (CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy)

  • Helene Goussault

    (IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, CHIC - Centre Hospitalier Intercommunal de Créteil, IIMTPIF - Institut Interuniversitaire de Médecine du Travail de Paris Ile-de-France)

  • Florence Canoui-Poitrine

    (IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, U955 Inserm - UPEC - IMRB - CEPIA/"Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health" [Créteil] - IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12)

  • Christos Chouaïd

    (CHIC - Centre Hospitalier Intercommunal de Créteil, U955 Inserm - UPEC - IMRB - CEPIA/"Clinical Epidemiology And Ageing : Geriatrics, Primary Care and Public Health" [Créteil] - IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - IFR10 - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12)

Abstract

Background: The National Lung Screening Trial (NLST) and NELSON study opened the debate on the relevance of lung cancer (LC) screening in subjects exposed to occupational respiratory carcinogens. This analysis reported the incremental cost-effectiveness ratios (ICER) of an organized LC screening program for an asbestos-exposed population. Methods: Using Markov modelization, individuals with asbestos exposure were either monitored without intervention or annual low-dose thoracic computed-tomography (LDTCT) scan LC screening. LC incidence came from a prospective observational cohort of subjects with occupational asbestos exposure. The intervention parameters were those of the NLST study. Utilities and LC-management costs came from published reports. A sensitivity analysis evaluated different screening strategies. Results: The respective quality-adjusted life year (QALY) gain, supplementary costs and ICER [95% confidence interval] were: 0.040 [0.010–0.065] QALY, 6900 [3700–11,800] € and 170,000 [75,000–645,000] €/QALY for all asbestos-exposed subjects; and 0.144 [0.071–0.216] QALY, 13,000 [5700–26,800] € and 90,000 [35,000–276,000] €/QALY for smokers with high exposure. When screening was based on biennial LDTCT scans, the ICER was 45,000 [95% CI: 15,000–116,000] €/QALY. Conclusions: Compared to the usual ICER thresholds, biennial LDTCT scan LC screening for smokers with high occupational exposure to asbestos is acceptable and preferable to annual scans.

Suggested Citation

  • Sébastien Gendarme & Jean-Claude Pairon & Pascal Andujar & François Laurent & Patrick Brochard & Fleur Delva & Bénédicte Clin & Antoine Gislard & Christophe Paris & Isabelle Thaon & Helene Goussault &, 2022. "Cost-Effectiveness of an Organized Lung Cancer Screening Program for Asbestos-Exposed Subjects," Post-Print hal-03783819, HAL.
    • Handle: RePEc:hal:journl:hal-03783819
    DOI: 10.3390/cancers14174089
    Note: View the original document on HAL open archive server: https://hal.science/hal-03783819v1
    as

    Download full text from publisher

    File URL: https://hal.science/hal-03783819v1/document
    Download Restriction: no
    File URL: https://libkey.io/10.3390/cancers14174089?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Julie Sturza, 2010. "A Review and Meta-Analysis of Utility Values for Lung Cancer," Medical Decision Making, , vol. 30(6), pages 685-693, November.
    2. Claire Williams & James D. Lewsey & Daniel F. Mackay & Andrew H. Briggs, 2017. "Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Mo," Medical Decision Making, , vol. 37(4), pages 427-439, May.
    3. Adam J. N. Raymakers & John Mayo & Stephen Lam & J. Mark FitzGerald & David G. T. Whitehurst & Larry D. Lynd, 2016. "Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 409-418, August.
    4. Andrea C Villanti & Yiding Jiang & David B Abrams & Bruce S Pyenson, 2013. "A Cost-Utility Analysis of Lung Cancer Screening and the Additional Benefits of Incorporating Smoking Cessation Interventions," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-11, August.
    5. Steven B. Markowitz, 2022. "Lung Cancer Screening in Asbestos-Exposed Populations," IJERPH, MDPI, vol. 19(5), pages 1-15, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Michael J. Zoratti & A. Simon Pickard & Peep F. M. Stalmeier & Daniel Ollendorf & Andrew Lloyd & Kelvin K W Chan & Don Husereau & John E. Brazier & Murray Krahn & Mitchell Levine & Lehana Thabane & Fe, 2021. "Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 723-733, July.
    2. Andrea C Villanti & Yiding Jiang & David B Abrams & Bruce S Pyenson, 2013. "A Cost-Utility Analysis of Lung Cancer Screening and the Additional Benefits of Incorporating Smoking Cessation Interventions," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-11, August.
    3. Khan, Abir & Sapuan, S.M. & Yusuf, J. & Siddiqui, Vasi Uddin & Zainudin, E.S. & Zuhri, M.Y.M. & Tuah Baharuddin, B.T. Hang & Ansari, Mubashshir Ahmad & Rahman, A. Azim A., 2023. "An examination of cutting-edge developments in Bamboo-PLA composite research: A comprehensive review," Renewable and Sustainable Energy Reviews, Elsevier, vol. 188(C).
    4. Olivia Pérol & Nadège Lepage & Hugo Noelle & Pierre Lebailly & Benoit de Labrusse & Bénédicte Clin & Mathilde Boulanger & Delphine Praud & Françoise Fournié & Géraud Galvaing & Frédéric Dutheil & Brig, 2023. "A Multicenter Study to Assess a Systematic Screening of Occupational Exposures in Lung Cancer Patients," IJERPH, MDPI, vol. 20(6), pages 1-15, March.
    5. John Edelsberg & Derek Weycker & Mark Atwood & Geoffrey Hamilton-Fairley & James R Jett, 2018. "Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-14, May.
    6. Andre Verhoek & Parneet Cheema & Barbara Melosky & Benoit Samson & Frances A. Shepherd & Filippo Marinis & Thomas John & Yi-Long Wu & Bart Heeg & Nadia Dalfsen & Benjamin Bracke & Miguel Miranda & Sim, 2023. "Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer," PharmacoEconomics - Open, Springer, vol. 7(3), pages 455-467, May.
    7. Holly L. Cranmer & Gemma E. Shields & Ash Bullement, 2023. "An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 385-394, May.
    8. Jiryoun Gong & Juhee Han & Donghwan Lee & Seungjin Bae, 2020. "A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience," IJERPH, MDPI, vol. 17(24), pages 1-16, December.
    9. Mathilda Bongers & Veerle Coupé & Elise Jansma & Egbert Smit & Carin Groot, 2012. "Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 30(1), pages 17-34, January.
    10. Mucahit Cevik & Mehmet Ali Ergun & Natasha K. Stout & Amy Trentham-Dietz & Mark Craven & Oguzhan Alagoz, 2016. "Using Active Learning for Speeding up Calibration in Simulation Models," Medical Decision Making, , vol. 36(5), pages 581-593, July.
    11. Carina M. Behr & Martijn J. Oude Wolcherink & Maarten J. IJzerman & Rozemarijn Vliegenthart & Hendrik Koffijberg, 2023. "Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations," PharmacoEconomics, Springer, vol. 41(4), pages 395-411, April.

    More about this item

    Keywords

    lung neoplasms; screening; occupational diseases; asbestos; cost-effectiveness;
    All these keywords.

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-03783819. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.